BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Debes JD, Janssen HLA, Boonstra A. Hepatitis C treatment and liver cancer recurrence: cause for concern? The Lancet Gastroenterology & Hepatology 2017;2:78-80. [DOI: 10.1016/s2468-1253(16)30204-7] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Invernizzi F, Colombo M. Pathway of care of hepatocellular carcinoma in 2017. Hepat Oncol 2016;3:217-21. [PMID: 30191044 DOI: 10.2217/hep-2017-0004] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
2 Kanda T, Nakamura M, Yasui S, Haga Y, Tawada A, Suzuki E, Ooka Y, Takahashi K, Sasaki R, Wu S, Nakamoto S, Arai M, Imazeki F, Yokosuka O. Treatment of Real-World HCV Genotype 2-Infected Japanese Patients with Sofosbuvir plus Ribavirin. Biology (Basel). 2017;6. [PMID: 28486403 DOI: 10.3390/biology6020030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
3 Pradat P, Virlogeux V, Trépo E. Epidemiology and Elimination of HCV-Related Liver Disease. Viruses 2018;10:E545. [PMID: 30301201 DOI: 10.3390/v10100545] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
4 Wong A, Tsien C, Mansour S, Cooper C. Remaining clinical issues in hepatitis C treatment. CanLivJ 2018;1:66-77. [DOI: 10.3138/canlivj.1.2.006] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Guo L, Sharma SD, Debes JD, Beisang D, Rattenbacher B, Vlasova-St Louis I, Wiesner DL, Cameron CE, Bohjanen PR. The hepatitis C viral nonstructural protein 5A stabilizes growth-regulatory human transcripts. Nucleic Acids Res 2018;46:2537-47. [PMID: 29385522 DOI: 10.1093/nar/gky061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]